Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Carisma Therapeutics Inc.SESN · Entity 74418 | Director | May 03, 2021 | May 10, 2021 |
| Invivyd, Inc.ADGI · Entity 721 | Chief Financial Officer | January 30, 2022 | February 01, 2022 |
| Voyager Therapeutics, Inc.VYGR · Entity 6271 | Sr. V.P. & CFO, Corp. Dev. | March 22, 2018 | March 26, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Carisma Therapeutics Inc.
Report date May 03, 2021 · Filed May 10, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.79 · Expires 2031-05-03 | Direct | 92,500 |
Reported balance
After 2021-05-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-03 · Grant · Acquired 92,500 · Balance 92,500 F1: The option was granted on May 3, 2021 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested. In April 2021, Sesen Bio, Inc.'s compensation committee, based on market analysis by Radford, recommended to the Sesen Bio, Inc. board of directors, and the board of directors approved, an increase in non-employee director equity compensation from the 50th percentile to the 75th percentile of the Radford market analysis of public, pre-commercial biopharmaceutical companies with less than 200 employees and market values between $250 million and $1 billion. The option granted to purchase 92,500 shares of Sesen Bio, Inc.'s common stock was equivalent to the 75th percentile of such Radford market analysis. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on May 3, 2021 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested. In April 2021, Sesen Bio, Inc.'s compensation committee, based on market analysis by Radford, recommended to the Sesen Bio, Inc. board of directors, and the board of directors approved, an increase in non-employee director equity compensation from the 50th percentile to the 75th percentile of the Radford market analysis of public, pre-commercial biopharmaceutical companies with less than 200 employees and market values between $250 million and $1 billion. The option granted to purchase 92,500 shares of Sesen Bio, Inc.'s common stock was equivalent to the 75th percentile of such Radford market analysis.
Invivyd, Inc.
Report date January 30, 2022 · Filed February 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.78 · Expires 2032-01-29 | Direct | 175,000 |
Reported balance
After 2022-01-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-01-30 · Grant · Acquired 175,000 · Balance 175,000 F1: This option vests in equal monthly installments over a four-year period measured from one month following January 30, 2022, subject to the Reporting Person's continuous service as of the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests in equal monthly installments over a four-year period measured from one month following January 30, 2022, subject to the Reporting Person's continuous service as of the applicable vesting date.
Voyager Therapeutics, Inc.
Report date March 22, 2018 · Filed March 26, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2018-03-23 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2018-03-22 · Exercise / conversion · Acquired 19,900 · Balance 19,900 Row 2 · 2018-03-22 · Sale · Disposed 19,900 · Balance 0 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.00 to $21.30, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., any security holder of Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Row 3 · 2018-03-23 · Exercise / conversion · Acquired 11,200 · Balance 11,200 Row 4 · 2018-03-23 · Sale · Disposed 11,200 · Balance 0 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.50 to $20.65, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., any security holder of Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.97 · Expires 2027-01-03 | Direct | 176,784 |
Reported balance
After 2018-03-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-03-22 · Exercise / conversion · Disposed 19,900 · Balance 176,784 F3: This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The option vests over four years, with 53,500 of the shares of common stock underlying the option vesting on 1/1/2018 and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.97 · Expires 2027-01-03 | Direct | 165,584 |
Reported balance
After 2018-03-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-03-23 · Exercise / conversion · Disposed 11,200 · Balance 165,584 F3: This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The option vests over four years, with 53,500 of the shares of common stock underlying the option vesting on 1/1/2018 and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.00 to $21.30, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., any security holder of Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.50 to $20.65, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., any security holder of Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
F3: This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The option vests over four years, with 53,500 of the shares of common stock underlying the option vesting on 1/1/2018 and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service.
Past disclosures · reporting ended (4)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Akero Therapeutics, Inc.
Report date December 09, 2025 · Filed December 09, 2025
Section 16 reporting ended · disclosed 2025-12-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 1
1 source rowRow 1 · 2025-12-09 · Disposition to issuer · Disposed 9,398 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 9, 2025 (such date and time, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo. F2: Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of common stock of the Issuer ("Company Common Stock") upon vesting of the Company RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive in respect of each such Company RSU (i) cash in an amount equal to $54.00 (the "Closing Consideration") and (ii) one contractual contingent value right (a "CVR") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement), without interest and subject to any withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.02 · Expires 2034-06-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-12-09 · Disposition to issuer · Disposed 26,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.83 · Expires 2033-06-23 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-12-09 · Disposition to issuer · Disposed 15,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.13 · Expires 2032-06-02 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-12-09 · Disposition to issuer · Disposed 15,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.32 · Expires 2031-06-01 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-12-09 · Disposition to issuer · Disposed 13,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.20 · Expires 2030-06-01 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-12-09 · Disposition to issuer · Disposed 13,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.01 · Expires 2029-04-03 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-12-09 · Disposition to issuer · Disposed 11,797 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 9, 2025 (such date and time, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo.
F2: Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of common stock of the Issuer ("Company Common Stock") upon vesting of the Company RSU.
F3: Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive in respect of each such Company RSU (i) cash in an amount equal to $54.00 (the "Closing Consideration") and (ii) one contractual contingent value right (a "CVR") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement), without interest and subject to any withholding taxes.
F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time.
Apogee Therapeutics, Inc.
Report date September 03, 2026 · Filed September 03, 2026
Section 16 reporting ended · disclosed 2026-09-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-09-03 transaction · row 1
1 source rowRow 1 · 2026-09-03 · Disposition to issuer · Disposed 158,371 · Balance 0 F1: The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the "Merger Agreement"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.86 · Expires 2033-12-18 | Direct | 0 |
Reported balance
After 2026-09-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-03 · Disposition to issuer · Disposed 175,345 · Balance 0 F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.07 · Expires 2034-12-09 | Direct | 0 |
Reported balance
After 2026-09-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-03 · Disposition to issuer · Disposed 124,962 · Balance 0 F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $75.78 · Expires 2036-01-02 | Direct | 0 |
Reported balance
After 2026-09-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-03 · Disposition to issuer · Disposed 83,690 · Balance 0 F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the "Merger Agreement"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc.
F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option.
CARGO Therapeutics, Inc.
Report date August 19, 2025 · Filed August 19, 2025
Section 16 reporting ended · disclosed 2025-08-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.35 · Expires 2035-06-17 | Direct | 0 |
Reported balance
After 2025-08-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-08-19 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 7, 2025, by and among CARGO Therapeutics, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub VII, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On August 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $4.379 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). [continues to Footnote 2] F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was canceled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3] F3: [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was canceled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 7, 2025, by and among CARGO Therapeutics, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub VII, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On August 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $4.379 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). [continues to Footnote 2]
F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was canceled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]
F3: [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was canceled for no consideration.
IVERIC bio, Inc.
Report date July 11, 2023 · Filed July 13, 2023
Section 16 reporting ended · disclosed 2023-07-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 1
1 source rowRow 1 · 2023-07-11 · Disposition to issuer · Disposed 22,088 · Balance 0 F1: On July 11, 2023, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated April 28, 2023, by and among IVERIC bio, Inc. ("IVERIC"), Astellas US Holding, Inc., Berry Merger Sub, Inc. ("Merger Sub") and, solely as provided by Section 8.10(b) of the Merger Agreement, Astellas Pharma Inc. ("Astellas"), Merger Sub merged with and into IVERIC, with IVERIC surviving the merger and becoming an indirect wholly owned subsidiary of Astellas (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of IVERIC common stock ("Common Stock") reported in this Form 4 was automatically cancelled and was converted into the right to receive $40.00 in cash, without interest and less any applicable withholding taxes. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-07-11 · Disposition to issuer · Disposed 7,500 · Balance 0 F2: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.85 · Expires 2028-01-12 | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-07-11 · Disposition to issuer · Disposed 32,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.78 · Expires 2028-05-22 | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-07-11 · Disposition to issuer · Disposed 16,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.39 · Expires 2029-05-14 | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-07-11 · Disposition to issuer · Disposed 16,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.14 · Expires 2030-06-08 | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-07-11 · Disposition to issuer · Disposed 16,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.82 · Expires 2031-05-18 | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-07-11 · Disposition to issuer · Disposed 15,500 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.94 · Expires 2032-05-11 | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-07-11 · Disposition to issuer · Disposed 23,186 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 11, 2023, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated April 28, 2023, by and among IVERIC bio, Inc. ("IVERIC"), Astellas US Holding, Inc., Berry Merger Sub, Inc. ("Merger Sub") and, solely as provided by Section 8.10(b) of the Merger Agreement, Astellas Pharma Inc. ("Astellas"), Merger Sub merged with and into IVERIC, with IVERIC surviving the merger and becoming an indirect wholly owned subsidiary of Astellas (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of IVERIC common stock ("Common Stock") reported in this Form 4 was automatically cancelled and was converted into the right to receive $40.00 in cash, without interest and less any applicable withholding taxes.
F2: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU.
F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU.
F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 11, 2023 Filed Jul 13, 2023 17:57 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Disposition to issuerStock Option (Right to Buy) · Derivative | 16,000 | Not disclosed Strike: $1.39 | Not disclosed |
DisclosureSEC source: 0001104659-23-080683 · tm2321002-4_4seq1.xml · derivative · entry 5 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2029-05-14 F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 17:57 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Disposition to issuerStock Option (Right to Buy) · Derivative | 16,000 | Not disclosed Strike: $2.78 | Not disclosed |
DisclosureSEC source: 0001104659-23-080683 · tm2321002-4_4seq1.xml · derivative · entry 4 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2028-05-22 F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 17:57 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Disposition to issuerStock Option (Right to Buy) · Derivative | 32,000 | Not disclosed Strike: $2.85 | Not disclosed |
DisclosureSEC source: 0001104659-23-080683 · tm2321002-4_4seq1.xml · derivative · entry 3 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,000 shares Expires 2028-01-12 F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 17:57 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Disposition to issuerRestricted Stock Units · Derivative | 7,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-080683 · tm2321002-4_4seq1.xml · derivative · entry 2 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires not disclosed F2 · derivative.exercise_price: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 17:57 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Disposition to issuerCommon Stock | 22,088 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-080683 · tm2321002-4_4seq1.xml · nonDerivative · entry 1 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On July 11, 2023, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated April 28, 2023, by and among IVERIC bio, Inc. ("IVERIC"), Astellas US Holding, Inc., Berry Merger Sub, Inc. ("Merger Sub") and, solely as provided by Section 8.10(b) of the Merger Agreement, Astellas Pharma Inc. ("Astellas"), Merger Sub merged with and into IVERIC, with IVERIC surviving the merger and becoming an indirect wholly owned subsidiary of Astellas (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of IVERIC common stock ("Common Stock") reported in this Form 4 was automatically cancelled and was converted into the right to receive $40.00 in cash, without interest and less any applicable withholding taxes. Read SEC document |
| June 23, 2023 Filed Jun 27, 2023 17:55 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $50.83 | $0.00 |
DisclosureSEC source: 0000950170-23-030220 · ownership.xml · derivative · entry 1 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-06-22 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 23, 2024 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 17:47 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $7.01 | $0.00 |
DisclosureSEC source: 0000950170-23-029228 · ownership.xml · derivative · entry 4 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,797 Underlying: Common Stock · 40,000 shares Expires 2029-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options are vested and currently exercisable. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 17:47 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 22,498 | $54.46 | $1,225,290.58 |
DisclosureSEC source: 0000950170-23-029228 · ownership.xml · nonDerivative · entry 3 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $54.20 to $55.135, inclusive. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 17:47 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 17,502 | $53.79 | $941,394.08 |
DisclosureSEC source: 0000950170-23-029228 · ownership.xml · nonDerivative · entry 2 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,498 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $53.20 to $54.17, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 17:47 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 40,000 | $7.01 | $280,400.00 |
DisclosureSEC source: 0000950170-23-029228 · ownership.xml · nonDerivative · entry 1 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2023 Filed May 19, 2023 21:49 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | GrantRestricted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001410939-23-000082 · wk-form4_1684532980.xml · derivative · entry 1 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the units. F2 · derivative.exercise_date: Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2023 Stock Incentive Plan, the award of restricted stock units will vest in full on the earlier of one business day prior to the Registrant's 2024 annual meeting of stockholders or the first anniversary of the grant date. Any unvested shares subject to the award of restricted stock units will be accelerated in full upon the occurrence of a change in control event (as defined in the Registrant's 2023 Stock Incentive Plan). For purposes of this report on Form 4, a change in control event includes the closing of the transaction contemplated by the Agreement and Plan of Merger, dated April 28, 2023, between the Registrant, Astellas US Holding, Inc., Berry Merger Sub, Inc. and solely as provided by Section 8.10(b) of such agreement, Astellas Pharma Inc. F2 · derivative.expiration_date: Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2023 Stock Incentive Plan, the award of restricted stock units will vest in full on the earlier of one business day prior to the Registrant's 2024 annual meeting of stockholders or the first anniversary of the grant date. Any unvested shares subject to the award of restricted stock units will be accelerated in full upon the occurrence of a change in control event (as defined in the Registrant's 2023 Stock Incentive Plan). For purposes of this report on Form 4, a change in control event includes the closing of the transaction contemplated by the Agreement and Plan of Merger, dated April 28, 2023, between the Registrant, Astellas US Holding, Inc., Berry Merger Sub, Inc. and solely as provided by Section 8.10(b) of such agreement, Astellas Pharma Inc. Read SEC document |
| May 11, 2023 Filed May 15, 2023 20:47 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Exercise / conversionRestricted Stock Units · Derivative | 14,588 | $0.00 | $0.00 |
DisclosureSEC source: 0001410939-23-000073 · wk-form4_1684183629.xml · derivative · entry 2 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,588 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F2 · derivative.exercise_date: In accordance with the Registrant's Non-Employee Director Compensation Policy, the Reporting Person was granted 14,588 of the Registrant's restricted stock units on May 12, 2022. Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units vested in full one business day prior to the first anniversary of the grant date. F2 · derivative.expiration_date: In accordance with the Registrant's Non-Employee Director Compensation Policy, the Reporting Person was granted 14,588 of the Registrant's restricted stock units on May 12, 2022. Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units vested in full one business day prior to the first anniversary of the grant date. Read SEC document |
| May 11, 2023 Filed May 15, 2023 20:47 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Exercise / conversionCommon Stock | 14,588 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001410939-23-000073 · wk-form4_1684183629.xml · nonDerivative · entry 1 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,088 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. Read SEC document |
| June 02, 2022 Filed Jun 3, 2022 16:06 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $8.13 | $0.00 |
DisclosureSEC source: 0000899243-22-020942 · doc4.xml · derivative · entry 1 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-01 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 2, 2023 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director. Read SEC document |
| May 12, 2022 Filed May 13, 2022 22:07 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | GrantStock Option (right to buy) · Derivative | 23,186 | $0.00 Strike: $9.94 | $0.00 |
DisclosureSEC source: 0001410939-22-000070 · wf-form4_165247958227090.xml · derivative · entry 4 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,186 Underlying: Common Stock · 23,186 shares Expires 2032-05-11 F4 · derivative.exercise_date: In accordance with the Registrant's Non-Employee Director Compensation Policy, the Reporting Person was granted a stock option to purchase 23,186 shares of the Registrant's common stock. Subject to the Reporting Person providing continued services to the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the stock option award will vest monthly with respect to 1/12 of the shares underlying such stock option award until the earlier of the business day immediately prior to the Registrant's 2023 annual meeting of stockholders or the first anniversary of the grant date. Any unvested shares subject to the stock option award will be accelerated in full upon the occurrence of a change in control event (as defined in the Registrant's 2013 Stock Incentive Plan). Read SEC document |
| May 12, 2022 Filed May 13, 2022 22:07 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | GrantRestricted Stock Units · Derivative | 14,588 | $0.00 | $0.00 |
DisclosureSEC source: 0001410939-22-000070 · wf-form4_165247958227090.xml · derivative · entry 3 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,588 Underlying: Common Stock · 14,588 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F3 · derivative.exercise_date: In accordance with the Registrant's Non-Employee Director Compensation Policy, the Reporting Person was granted 14,588 restricted stock units. Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest in full on the earlier of one business day prior to the Registrant's 2023 annual meeting of stockholders or the first anniversary of the grant date. Any unvested shares subject to the award of restricted stock units will be accelerated in full upon the occurrence of a change in control event (as defined in the Registrant's 2013 Stock Incentive Plan). F3 · derivative.expiration_date: In accordance with the Registrant's Non-Employee Director Compensation Policy, the Reporting Person was granted 14,588 restricted stock units. Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest in full on the earlier of one business day prior to the Registrant's 2023 annual meeting of stockholders or the first anniversary of the grant date. Any unvested shares subject to the award of restricted stock units will be accelerated in full upon the occurrence of a change in control event (as defined in the Registrant's 2013 Stock Incentive Plan). Read SEC document |
| May 11, 2022 Filed May 13, 2022 22:07 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Exercise / conversionRestricted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001410939-22-000070 · wf-form4_165247958227090.xml · derivative · entry 2 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F2 · derivative.exercise_date: On May 19, 2021, the Reporting Person was granted 7,500 restricted stock units, which vest in full upon on the earlier of one business day prior to the Registrant's 2022 annual meeting of stockholders or the first anniversary of the grant date. F2 · derivative.expiration_date: On May 19, 2021, the Reporting Person was granted 7,500 restricted stock units, which vest in full upon on the earlier of one business day prior to the Registrant's 2022 annual meeting of stockholders or the first anniversary of the grant date. Read SEC document |
| May 11, 2022 Filed May 13, 2022 22:07 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Exercise / conversionCommon Stock | 7,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001410939-22-000070 · wf-form4_165247958227090.xml · nonDerivative · entry 1 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. Read SEC document |
| January 30, 2022 Filed Feb 1, 2022 23:15 UTC | Invivyd, Inc. ADGI · Entity 721 | GrantStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $6.78 | $0.00 |
DisclosureSEC source: 0001209191-22-006024 · doc4.xml · derivative · entry 1 Henderson Jane · CIK 0001422304 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2032-01-29 F1 · derivative.exercise_date: This option vests in equal monthly installments over a four-year period measured from one month following January 30, 2022, subject to the Reporting Person's continuous service as of the applicable vesting date. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 17:58 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GrantStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $26.32 | $0.00 |
DisclosureSEC source: 0001104659-21-076500 · tm2118278-6_4seq1.xml · derivative · entry 1 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2031-05-31 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 1, 2022 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director. Read SEC document |
| May 19, 2021 Filed May 20, 2021 23:54 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | GrantRestricted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-070100 · tm2117174-4_4seq1.xml · derivative · entry 2 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the units. F3 · derivative.exercise_date: Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest in full on the earlier of one business day prior to the Registrant's 2022 annual meeting of stockholders or the first anniversary of the grant date. Any unvested shares subject to the award of restricted stock units will be accelerated in full upon the occurrence of a change in control event (as defined in the Registrant's 2013 Stock Incentive Plan). F3 · derivative.expiration_date: Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest in full on the earlier of one business day prior to the Registrant's 2022 annual meeting of stockholders or the first anniversary of the grant date. Any unvested shares subject to the award of restricted stock units will be accelerated in full upon the occurrence of a change in control event (as defined in the Registrant's 2013 Stock Incentive Plan). Read SEC document |
| May 19, 2021 Filed May 20, 2021 23:54 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | GrantStock Option (Right to Buy) · Derivative | 15,500 | $0.00 Strike: $6.82 | $0.00 |
DisclosureSEC source: 0001104659-21-070100 · tm2117174-4_4seq1.xml · derivative · entry 1 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,500 Underlying: Common Stock · 15,500 shares Expires 2031-05-18 F1 · derivative.exercise_date: Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the stock option award will vest monthly with respect to 1/12 of the shares underlying such stock option award until the earlier of the business day immediately prior to the Registrant's 2022 annual meeting of stockholders or the first anniversary of the grant date. Any unvested shares subject to the stock option award will be accelerated in full upon the occurrence of a change in control event (as defined in the Registrant's 2013 Stock Incentive Plan). Read SEC document |
| May 03, 2021 Filed May 10, 2021 20:45 UTC | Carisma Therapeutics Inc. SESN · Entity 74418 | GrantStock Option · Derivative | 92,500 | $0.00 Strike: $2.79 | $0.00 |
DisclosureSEC source: 0001485003-21-000110 · wf-form4_162069392081695.xml · derivative · entry 1 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,500 Underlying: Common Stock · 92,500 shares Expires 2031-05-03 F1 · derivative.exercise_date: The option was granted on May 3, 2021 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested. In April 2021, Sesen Bio, Inc.'s compensation committee, based on market analysis by Radford, recommended to the Sesen Bio, Inc. board of directors, and the board of directors approved, an increase in non-employee director equity compensation from the 50th percentile to the 75th percentile of the Radford market analysis of public, pre-commercial biopharmaceutical companies with less than 200 employees and market values between $250 million and $1 billion. The option granted to purchase 92,500 shares of Sesen Bio, Inc.'s common stock was equivalent to the 75th percentile of such Radford market analysis. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 18:01 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0001104659-20-072339 · a4.xml · derivative · entry 1 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires not disclosed F1 · derivative.exercise_date: Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the option will vest and become exercisable in 12 consecutive, equal installments on each consecutive monthly anniversary of the date of grant, until fully vested and exercisable on the first anniversary of the date of grant. Any unvested shares subject to the option will be accelerated in full one business day prior to the Registrant's 2021 annual meeting of stockholders. F1 · derivative.expiration_date: Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the option will vest and become exercisable in 12 consecutive, equal installments on each consecutive monthly anniversary of the date of grant, until fully vested and exercisable on the first anniversary of the date of grant. Any unvested shares subject to the option will be accelerated in full one business day prior to the Registrant's 2021 annual meeting of stockholders. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 18:54 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GrantStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $25.20 | $0.00 |
DisclosureSEC source: 0001104659-20-069077 · a4.xml · derivative · entry 1 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2030-05-31 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director. Read SEC document |
| May 06, 2020 Filed May 8, 2020 17:49 UTC | Carisma Therapeutics Inc. SESN · Entity 74418 | GrantStock Option · Derivative | 59,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001485003-20-000054 · wf-form4_158897457961477.xml · derivative · entry 1 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 Underlying: Common Stock · 59,000 shares Expires 2030-05-06 F1 · derivative.exercise_date: The option was granted on May 6, 2020 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 16:12 UTC | Carisma Therapeutics Inc. SESN · Entity 74418 | GrantStock Option · Derivative | 52,500 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001485003-19-000040 · wf-form4_156114795621041.xml · derivative · entry 1 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 52,500 shares Expires 2029-06-18 F1 · derivative.exercise_date: The option was granted on June 19, 2019 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested. Read SEC document |
| May 15, 2019 Filed May 16, 2019 21:13 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0001104659-19-030032 · a4.xml · derivative · entry 1 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2029-05-14 F1 · derivative.exercise_date: Subject to Reporting Person providing continued services to the Issuer and other terms and conditions under the Issuer's 2013 Stock Incentive Plan, the option will vest and become exercisable in 12 consecutive, equal installments on each consecutive monthly anniversary of the date of grant, until fully vested and exercisable on the first anniversary of the date of grant. Any unvested shares subject to the option will be accelerated in full one business day prior to the Issuer's 2020 annual meeting of stockholders. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 16:08 UTC | Carisma Therapeutics Inc. SESN · Entity 74418 | GrantStock Option · Derivative | 52,500 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001485003-18-000091 · wf-form4_152900690635319.xml · derivative · entry 1 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 52,500 shares Expires 2028-06-11 F1 · derivative.exercise_date: The option was granted on June 12, 2018 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested. Read SEC document |
| May 23, 2018 Filed Jul 11, 2018 20:47 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001104659-18-044689 · a4.xml · derivative · entry 1 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2028-05-22 F1 · derivative.exercise_date: Subject to Reporting Person providing continued services to the Issuer and other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the option will vest and become exercisable in 12 consecutive, equal installments on each consecutive monthly anniversary of the date of grant, until fully vested and exercisable on the first anniversary of the date of grant. Any unvested shares subject to the option will be accelerated in full one business day prior to the Issuer's 2019 annual meeting of stockholders. Read SEC document |
| March 23, 2018 Filed Mar 26, 2018 20:02 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,200 | $0.00 Strike: $11.97 | $0.00 |
DisclosureSEC source: 0001104659-18-020100 · a4.xml · derivative · entry 6 Henderson Jane · CIK 0001422304 · Sr. V.P. & CFO, Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,584 Underlying: Common Stock · 11,200 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The option vests over four years, with 53,500 of the shares of common stock underlying the option vesting on 1/1/2018 and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service. Read SEC document |
| March 23, 2018 Filed Mar 26, 2018 20:02 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 11,200 | $20.52 | $229,824.00 |
DisclosureSEC source: 0001104659-18-020100 · a4.xml · nonDerivative · entry 4 Henderson Jane · CIK 0001422304 · Sr. V.P. & CFO, Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.50 to $20.65, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., any security holder of Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| March 23, 2018 Filed Mar 26, 2018 20:02 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | Exercise / conversionCommon Stock | 11,200 | $11.97 | $134,064.00 |
DisclosureSEC source: 0001104659-18-020100 · a4.xml · nonDerivative · entry 3 Henderson Jane · CIK 0001422304 · Sr. V.P. & CFO, Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 22, 2018 Filed Mar 26, 2018 20:02 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | Exercise / conversionStock Option (Right to Buy) · Derivative | 19,900 | $0.00 Strike: $11.97 | $0.00 |
DisclosureSEC source: 0001104659-18-020100 · a4.xml · derivative · entry 5 Henderson Jane · CIK 0001422304 · Sr. V.P. & CFO, Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,784 Underlying: Common Stock · 19,900 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The option vests over four years, with 53,500 of the shares of common stock underlying the option vesting on 1/1/2018 and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service. Read SEC document |
| March 22, 2018 Filed Mar 26, 2018 20:02 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 19,900 | $21.07 | $419,293.00 |
DisclosureSEC source: 0001104659-18-020100 · a4.xml · nonDerivative · entry 2 Henderson Jane · CIK 0001422304 · Sr. V.P. & CFO, Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.00 to $21.30, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., any security holder of Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| March 22, 2018 Filed Mar 26, 2018 20:02 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | Exercise / conversionCommon Stock | 19,900 | $11.97 | $238,203.00 |
DisclosureSEC source: 0001104659-18-020100 · a4.xml · nonDerivative · entry 1 Henderson Jane · CIK 0001422304 · Sr. V.P. & CFO, Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 19, 2018 Filed Mar 20, 2018 21:43 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,900 | $0.00 Strike: $11.97 | $0.00 |
DisclosureSEC source: 0001104659-18-019018 · a4.xml · derivative · entry 6 Henderson Jane · CIK 0001422304 · CFO & SVP, Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,684 Underlying: Common Stock · 1,900 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The option vests over four years, with 53,500 of the shares of common stock underlying the option vesting on 1/1/2018 and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service. Read SEC document |
| March 19, 2018 Filed Mar 20, 2018 21:43 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 1,900 | $21.76 | $41,344.00 |
DisclosureSEC source: 0001104659-18-019018 · a4.xml · nonDerivative · entry 4 Henderson Jane · CIK 0001422304 · CFO & SVP, Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.75 to $21.80, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., any security holder of Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| March 19, 2018 Filed Mar 20, 2018 21:43 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | Exercise / conversionCommon Stock | 1,900 | $11.97 | $22,743.00 |
DisclosureSEC source: 0001104659-18-019018 · a4.xml · nonDerivative · entry 3 Henderson Jane · CIK 0001422304 · CFO & SVP, Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2018 Filed Mar 20, 2018 21:43 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,416 | $0.00 Strike: $11.97 | $0.00 |
DisclosureSEC source: 0001104659-18-019018 · a4.xml · derivative · entry 5 Henderson Jane · CIK 0001422304 · CFO & SVP, Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,584 Underlying: Common Stock · 15,416 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The option vests over four years, with 53,500 of the shares of common stock underlying the option vesting on 1/1/2018 and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service. Read SEC document |
| March 16, 2018 Filed Mar 20, 2018 21:43 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 15,416 | $22.15 | $341,464.40 |
DisclosureSEC source: 0001104659-18-019018 · a4.xml · nonDerivative · entry 2 Henderson Jane · CIK 0001422304 · CFO & SVP, Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $22.42, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., any security holder of Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| March 16, 2018 Filed Mar 20, 2018 21:43 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | Exercise / conversionCommon Stock | 15,416 | $11.97 | $184,529.52 |
DisclosureSEC source: 0001104659-18-019018 · a4.xml · nonDerivative · entry 1 Henderson Jane · CIK 0001422304 · CFO & SVP, Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,416 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 07, 2018 Filed Mar 10, 2018 00:11 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $28.72 | $0.00 |
DisclosureSEC source: 0001104659-18-016413 · a4.xml · derivative · entry 1 Henderson Jane · CIK 0001422304 · Sr. V.P. & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2028-03-07 F1 · derivative.exercise_date: This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of the Vesting Commencement Date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service. Read SEC document |
| January 13, 2018 Filed Jan 17, 2018 22:06 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | GrantStock Option (Right to Buy) · Derivative | 32,000 | $0.00 Strike: $2.85 | $0.00 |
DisclosureSEC source: 0001104659-18-002660 · a4.xml · derivative · entry 1 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2028-01-12 F1 · derivative.exercise_date: The vesting commencement date ("Vesting Commencement Date") of the option is January 13, 2018. The option vests with respect to one-thirty sixth (1/36th) of the shares underlying the option, on each monthly anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| May 19, 2017 Filed May 23, 2017 16:43 UTC | Carisma Therapeutics Inc. EBIO · Entity 74418 | GrantStock Option · Derivative | 8,072 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001485003-17-000065 · wf-form4_149557216490440.xml · derivative · entry 1 Henderson Jane · CIK 0001422304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,072 Underlying: Common Stock · 8,072 shares Expires 2027-05-18 F1 · derivative.exercise_date: The option was granted on May 19, 2017 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 22:26 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 214,000 | $0.00 Strike: $11.97 | $0.00 |
DisclosureSEC source: 0001104659-17-000985 · a4.xml · derivative · entry 1 Henderson Jane · CIK 0001422304 · Sr. V.P. & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,000 Underlying: Common Stock · 214,000 shares Expires 2027-01-03 F1 · derivative.exercise_date: These stock options were issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. 53,500 of the shares of common stock underlying the options will vest on 1/1/2018 and the remainder will vest in 36 equal monthly installments thereafter, subject to continued service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.